Seres Therapeutics Inc. (NASDAQ:MCRB) does about 2.84M shares in volume on a normal day but saw 1378805 shares change hands in Friday trading. The company now has a market cap of 2.21B USD and an enterprise value of about $2.19B. Its current market price is $24.58, marking a decrease of -2.42% compared to the previous close of $25.19. The 52 week high reached by this stock is $33.00 whilst the lowest price level in 52 weeks is $2.52. The script in recent trading has seen the stock touch a high of $26.41 and a low of $24.15.
Seres Therapeutics Inc. (MCRB) has a 20-day trading average at $14.44 and the current price is -25.52% off the 52-week high compared with 875.40% distance from its 52-week low. The 50-day simple moving average of the closing price is $8.63 and its 200-day simple moving average is $5.02. If we look at the stock’s price movements over the week, volatility stands at 9.99%, which increases to 14.67% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 73.11 to suggest the stock is overbought.
8 analysts observing the Seres Therapeutics Inc. (MCRB) stock have set the 12-month price targets for the company’s shares at between $24.00 and $41.00. The consensus objective for the share price is $30.93, suggesting that the stock has a potential upside of 20.53% over the period. The median price target is 24.37% away from the current levels at $32.50.
FactSet Research has provided data showing that 8 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 7 analysts have rated it as a buy and 1 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on August 18, 2020 when Piper Sandler initiated the stock to “Overweight” and issued a price target of $40. Jefferies upgraded the stock to “Buy” from Hold on August 11, 2020 at a price target of $4-$29. H.C. Wainwright reiterated its price target at $8-$41.
The current price level is 83.23%, 198.90%, and 400.08% away from its SMA20, SMA50, and SMA200 respectively, with the MCRB price moving below the 50-day SMA on August 21. Seres Therapeutics Inc. (MCRB) stock is down -9.83% over the week and 456.11% over the past month. Its price is 612.46% year-to-date and 553.72% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of -$0.28 below consensus estimates by -$0.02. The company’s next earnings report is expected on 11/05/2020, with forecasts estimating quarterly EPS at -$0.26 and -$0.97 for whole year. MCRB’s earnings per share are forecast to grow by 21.80% this year and -36.10% over next year. Expected sales for next quarter are $7.54 million, which analysts say will come at $29.03 million for the current fiscal year and next year at $32.85 million. In addition, estimates put the company’s current quarterly revenue at an average of $7.26 million.
Its 12-month price target is $32.50. To reach the target analysts have set, the stock logically needs to grow 20.53 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $24.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $41.00.
Outstanding shares total 73.31M with insiders holding 10.00% of the shares and institutional holders owning 80.15% of the company’s common stock. The company has a return on investment of 303.30% and return on equity of 145.90%. The beta has a value of 2.51. Price to sales ratio is 76.45.
According to a U.S. Securities and Exchange Commission filing, ARK Innovation ETF has added its position in Seres Therapeutics Inc. (MCRB) to 8,718,492 shares, mirroring a recent increase by 1.08%. ARK Innovation ETF added 93143.0 shares of Seres Therapeutics Inc. common stock bringing its total worth to about $32.61 million at the end of recent close, SEC documents show. ARK Innovation ETF isn’t the only investment manager who changed stakes and is followed by Nikko AM Global Umbrella Fund – A, which added 5.38 million shares to end up with 5,434,478 shares worth $20.32 million. ARK Genomic Revolution ETF cut their holdings by -1.13% in the company over the course of the most recent quarter. It now holds a 4.58% position in Seres Therapeutics Inc. thanks to 3.49 million shares amounting to $13.05 million.